Based on CEM/CMO/2022/007 interim clinical commissioning policy published 5th May 2022.
NOTE: this is an unlicensed indication for baricitinib.
Prescribing is restricted to the consultant caring for patient that day who takes full responsibility for use
Baricitinib is a selective, reversible Janus kinase (JAK) 1 and 2 inhibitor, thought to control high levels of cytokines and inflammation seen in severe SARS-CoV-2 infection.
Clinical trials results show a 28 day mortality reduction from 14% to 12%, in addition to other treatments for SARS-CoV-2 (COVID-19) infection (corticosteroid, IL-6 inhibitor or remdesivir).
Baricitinib is licensed for use in moderate to severe rheumatoid arthritis and moderate to severe atopic dermatitis.